07:48:40 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-21 Bokslutskommuniké 2024
2024-08-09 Halvårsrapport
2024-06-13 Årsstämma
2024-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2024-02-26 Bokslutskommuniké 2023
2023-10-23 Extra Bolagsstämma 2023
2023-08-25 Halvårsrapport
2023-05-02 X-dag ordinarie utdelning BONEH 0.00 EUR
2023-04-28 Årsstämma
2023-02-24 Bokslutskommuniké 2022
2022-08-25 Halvårsrapport
2022-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Halvårsrapport
2021-04-29 X-dag ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Halvårsrapport
2020-04-06 X-dag ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Halvårsrapport
2019-04-08 X-dag ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma
2018-08-30 Halvårsrapport
2018-03-29 Årsstämma

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamt inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2024-01-02 15:30:00

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 2 January 2024 at 04.30 PM (EET)

Kimmo Tyni appointed as Product Director of BBS-Bioactive Bone Substitutes Plc

BBS-Bioactive Bone Substitutes Plc has appointed Kimmo Tyni (B. Sc. Tech.) as Product Director as of 15.1.2024. The current Product Director Jussi Jukka will transfer from company’s service, to outside of BBS. Tyni will work as a member of the management team of BBS and report to the CEO.

Tyni has previous experience in manufacturing processes of medical devices and the standards governing them. He has also worked in companies similar to BBS, where a company is transitioning from a product development to commercial manufacturing.

"I welcome Kimmo to our company and I am sure that we will gain experience and know-how from him at this critical stage where the company is preparing to move from a product development company to a commercial phase and industrial production. I would also like to thank Jussi for his work in developing BBS's production and wish him good luck and success in his new challenges", says Juliusz Rakowski, CEO of BBS.


For more information, please contact:
Juliusz Rakowski, CEO

+358 50 448 5132

juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB,

+46 70 551 67 29,

info@certifiedadviser.se


BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.
BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi